Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imipramine SCHEMBL17004048 | 1.00 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL29350100 | 1.00 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL6118138 | 1.00 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL41766 | 0.98 | LMNA (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL29040915 | 0.98 | SLC6A4 (0.97) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL41765 | 0.98 | LMNA (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL28759733 | 0.98 | LMNA (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL27657924 | 0.98 | SLC6A4 (0.97) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL15719828 | 0.97 | LMNA (0.97) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL3002670 | 0.97 | SLC6A4 (0.94) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 52072 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-0093373-A1 | Method and composition for treating and preventing irritation of the mucous membranes of the nose | Bernstein, Joel E. (US) | 1983-11-09 | — | — | EP | claimed |
| US-4370324-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1983-01-25 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| EP-0044441-A1 | Monoclonal antibodies to drugs, methods for their production and somatic cell hybridomas secreting them | MILES LABORATORIES, INC. (US) | 1982-01-27 | — | — | EP | claimed |
| US-4310524-A | TCA Composition and method for rapid onset antidepressant therapy | RICHARDSON-MERRELL, INC. (US) | 1982-01-12 | — | — | US | claimed |
| US-4279992-A | Specific binding assay employing an enzyme-cleavable substrate as label | MILES LABORATORIES, INC. (US) | 1981-07-21 | — | — | US | claimed |
| US-4249003-A | Process for polycyclic amines | AKTIEBOLAGET LEO (SE) | 1981-02-03 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-3993072-A | Microporous drug delivery device | ALZA CORPORATION (US) | 1976-11-23 | — | — | US | claimed |
| US-3961060-A | DOPA, M-TYROSINE, APOMORPHINE, PIPERAZINE DERIVATIVE | ASTRA LAKEMEDAL AKTIEBOLAG (SW) | 1976-06-01 | — | — | US | claimed |